Gentian Diagnostics - Third quarter 2026 report

Moss 20 October, 2026

Gentian Diagnostics ASA, a fast-growing developer and manufacturer of diagnostic
tests, today announced its results for the third quarter of 2026.

Highlights include:

Record sales: Sales of NOK 51.1 million (41.8), up 22% reported and 30% currency
neutral organic growth, with a currency headwind of 3.2 million. YTD sales of
NOK 144.8 million (129.9), up 11% (17% currency neutral organic growth).

Growth drivers: fCAL turbo sales up 23% in Q3 (22% YTD) through BÜHLMANN. US
sales up 23% in Q3 (49% YTD), driven by Cystatin C. Asia down -33% YTD due to
pricing and testing restrictions in China.

Improved profitability: EBITDA of NOK 13.6 million (8.4), an EBITDA margin of
27% (20%). Gross margin of 61% (56%), driven by higher production yields and a
favourable geographic sales mix. YTD EBITDA of NOK 26.7 million (24.1) and gross
margin of 56% (55%).

Non-recurring items: Q3 2026 operating profit is not affected by non-recurring
items. YTD results include a non-cash impairment of NOK 30.2 million in Q1
related to the discontinued NT-proBNP project (included in R&D expenses,
excluded from EBITDA). The underlying operating performance YTD improved
compared with the same period last year when taking the impairment charge in
Q1'26 into account. The reported YTD net result was NOK -8.5 million (9.8).

Comparability: All R&D costs are expensed in 2026, while NOK 1.3 million in Q3
2025 and NOK 5.5 million YTD 2025 were capitalised. The year-on-year improvement
in profitability is therefore stronger than reflected in the reported EBITDA
development. YTD sales include NOK 2.8 million in milestone-based development
revenue (none in Q3).

Cash flow: Operating cash flow of NOK 14.9 million (8.9) in Q3. YTD operating
cash flow of NOK -0.9 million (16.5), mainly reflecting an increase in
receivables of NOK 17.8 million. Cash of NOK 91.4 million at quarter end, after
NOK 9.3 million in dividends paid in May.

Pipeline on track: The assay for a key IVD partner progressed from research to
development and remains on track for launch in Q4 2027. Development work with
Essange Reagents has started, and altogether seven assay and one technology
development projects are active.

Webcast 
The company will present the results today at 09.00 am, followed by a Q&A
session. The presentation will be held as a live webcast on the company's
website: 

https://www.gentian.com/investor-relation/presentations

The webcast will also be available on the company website after the
presentation. 

IR contact:
Njaal Kind, CFO 
njaal.kind@gentian.no 
+47 919 06 525 (mobile)

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to Section 5-12 in the Norwegian Securities Trading Act. This stock exchange
announcement was published by Njaal Kind, Chief Financial Officer at Gentian
Diagnostics ASA, on 20 October 2026 at 08:00 CET. 

About Gentian Diagnostics 
Gentian Diagnostics (OSE: GENT), develops and manufactures high-quality, in
vitro diagnostic reagents. Our mission is to innovate diagnostic efficiency for
better treatment decisions.  Gentian's expertise and focus lie within
immunoassays, specifically for infections, inflammation, kidney disease and
heart failure. By converting existing and clinically relevant biomarkers to the
most efficient, high-throughput analysers, the company contributes to saving
costs and protecting life. Gentian Diagnostics is headquartered in Moss, Norway,
serving the global human and veterinary diagnostics markets through sales and
representative offices in Sweden, USA, and China. For more information, please
visit www.gentian.com.
representative offices in Sweden\, USA\, and China. For more information\, please\
visit www.gentian.com.\